Logo Annals of Transplantation Logo Annals of Transplantation Logo Annals of Transplantation

13 December 1996

Kinetics of in vitro immuneresponses of , and B cells during tolerance induction by sirolimus

R Ghobrial, M Karczewski, M Ferraresso, L Tian, S M Stepkowski, B D Kahan

Ann Transplant 1996; 1(4): 22-29 :: ID: 496681


Objectives: The purpose of the study presented herein was to examine immune performances of rat heart allograft recipients immunosuppressed with sirolimus (SRL.rapamycin;Rapamune.Wyeth-Ayerst. Princeton, NJ). Methods: The immune performances of lymphocytes harvested from SRL-treated Wistar Furth (WF; RT I") recipients of Buffalo (BUF; RT Ib) heart allografts were examined on days 7. 14. and 90 postgrafting. Results: Whether derived from normal WF rats, SRL-treated WF heart recipients. or SRL-untreated WF heart recipients. pan- T cell populations purified from the lymph nodes or spleens on day 7 or 14 displayed similar responses to phytohemaglutinin. anti- T cell receptor R73 monoclonal antibody, donor-type BUF. or third-party Brown Norway alloantigenic stimulators. There was no in vitro evidence of suppressor T cells in SRL-treated recipients. The frequencies of anti-BUF-specific cytotoxic T cells. as shown by limiting dilution analysis, were similar in the short- (days 7 or 14) and in the long- (day 90) term surviving recipients. SRL treatment did not affect the expression of interleukin-2 (IL-2) messenger RNA (mRNA) by T helper I (Thl) or of IL-4 and IL-IO mRNA by Th2 cells on days 7 and 14 postgrafting, but did induce selective activation of Th2 cells on day 60 postgrafting. Administration of SRL induced the production of non-complement (C)-fixing IgG2c BUF-specific alloantibodies that appeared in the sera of unresponsive recipients on day 14 postgrafting and reached a peak concentration on day 120 postgrafting. In contrast to untreated recipients that rejected BUF heart allografts, all SRL-treated WF recipients failed to produce C-fixing BUF-specific alloantibodies. Conclusions: SRL promotes long-term selective activation of Th2 cells and the production of non-C -fixing IgG2c blocking antibodies.

Keywords: Sirolimus, immunosuppresion, Heart Transplantation, in vitro performances


Most Viewed Current Articles

26 Jan 2022 : Review article  

Recurrence of Hepatocellular Carcinoma After Liver Transplantation: Risk Factors and Predictive Models

DOI :10.12659/AOT.934924

Ann Transplant 2022; 27:e934924

24 Aug 2021 : Review article  

Normothermic Machine Perfusion (NMP) of the Liver – Current Status and Future Perspectives

DOI :10.12659/AOT.931664

Ann Transplant 2021; 26:e931664

29 Dec 2021 : Original article  

Efficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...

DOI :10.12659/AOT.933588

Ann Transplant 2021; 26:e933588

15 Mar 2022 : Case report  

Combined Liver, Pancreas-Duodenum, and Kidney Transplantation for Patients with Hepatitis B Cirrhosis, Urem...

DOI :10.12659/AOT.935860

Ann Transplant 2022; 27:e935860

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Annals of Transplantation eISSN: 2329-0358
Annals of Transplantation eISSN: 2329-0358